Hyloris Pharmaceuticals (HYL) Investor Presentation summary

Company overview

• Focuses on reformulating and repurposing existing chemical entities to address unmet medical needs, aiming to become a market leader in value-added medicines.

• Portfolio targets 30 cardiovascular and other value-added assets, with a patient-centric, lower-risk development model.

• Based in Liège, Belgium, founded in 2012, and listed on Euronext Brussels; co-founders hold 41% of shares.

• Executive team has deep expertise in regulatory affairs, market access, and capital markets, with involvement in over 80 approved drugs and 300+ licensing transactions.

Business model and strategy

• Develops patented, value-added medicines by reformulating or repurposing off-patent compounds, focusing on efficacy, safety, compliance, and convenience.

• Utilizes a repurposing model that reduces risk, cost, and time-to-market to under 7 years, compared to traditional drug discovery.

• Prioritizes products with clear scientific rationale, regulatory pathways, and technical feasibility, aiming for fast market adoption and maximized ROI.

• Targets development costs below €7 million per asset and seeks to address clear unmet needs with strong patent protection.

Product portfolio

• Cardiovascular portfolio includes Sotalol IV, Aspirin IV, Milrinone Extended Release, Dofetilide IV, Metolazone IV, and other late-stage assets, with some commercialized in partnership.

• Other value-added products address indications such as post-operative pain (Maxigesic IV), genital warts (Podofilox Gel), ADHD, viral infections, and rare diseases.

• Recent pipeline additions include treatments for Burning Mouth Syndrome (HY-090), Vulvar Lichen Sclerosus (HY-091), and Equine Gastric Ulcer Syndrome (HY-095), all targeting significant unmet needs.

• Notable pipeline assets: Alenura for interstitial cystitis, HY-083 for idiopathic rhinitis, PTX-252 for AML and SCLC, and Milrinone Extended Release for heart failure with LVAD.